No Data
No Data
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
iTeos Therapeutics (ITOS) said Monday it has dosed the first patient in its phase 3 trial of belrestotug with dostarlimab, triggering a $35 million development milestone payment from its belrestotug p
Express News | Iteos Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones From GSK
Sector Update: Health Care Stocks Advance in Afternoon Trading
Health care stocks were rising Friday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) gained 0.4%.
ITeos, Arcus Shares Drop After Genentech's Lung Cancer Study Misses Endpoints
iTeos Therapeutics (ITOS) and Arcus Biosciences (RCUS) shares fell in early Friday trading after Roche Group's Genentech said its phase 2/3 non-small cell lung cancer study failed to meet its primary
Express News | Shares of Compugen Down 3%, Iteos Therapeutics Down 6.1%, and Arcus Biosciences Down 3.8%
Express News | Anti-Tigit Drugmakers Fall as Roche's Lung Cancer Drug Fails Trial